Lisa Hines
Concepts (366)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 52 | 2024 | 2253 | 3.520 |
Why?
| | Receptors, Estrogen | 12 | 2024 | 436 | 1.710 |
Why?
| | Receptors, Progesterone | 8 | 2024 | 350 | 1.270 |
Why?
| | Genetic Predisposition to Disease | 23 | 2017 | 2426 | 1.110 |
Why?
| | Menopause | 9 | 2024 | 320 | 1.090 |
Why?
| | Case-Control Studies | 37 | 2024 | 3556 | 0.930 |
Why?
| | Polymorphism, Single Nucleotide | 21 | 2022 | 2189 | 0.820 |
Why?
| | Receptor, ErbB-2 | 2 | 2024 | 341 | 0.780 |
Why?
| | Alcohol Drinking | 9 | 2017 | 828 | 0.750 |
Why?
| | Emigrants and Immigrants | 1 | 2023 | 136 | 0.680 |
Why?
| | Risk Factors | 39 | 2024 | 10388 | 0.650 |
Why?
| | Middle Aged | 58 | 2024 | 33479 | 0.560 |
Why?
| | Coronary Disease | 3 | 2005 | 385 | 0.530 |
Why?
| | Adult | 57 | 2024 | 37929 | 0.500 |
Why?
| | Adenylyl Cyclases | 2 | 2006 | 87 | 0.500 |
Why?
| | Aged | 48 | 2024 | 23961 | 0.490 |
Why?
| | Parity | 5 | 2024 | 126 | 0.480 |
Why?
| | Alcohol Dehydrogenase | 3 | 2005 | 15 | 0.470 |
Why?
| | Genetics | 1 | 2014 | 23 | 0.430 |
Why?
| | Female | 69 | 2024 | 73304 | 0.420 |
Why?
| | Suicide, Attempted | 1 | 2017 | 378 | 0.420 |
Why?
| | Substance-Related Disorders | 2 | 2017 | 1083 | 0.410 |
Why?
| | Science | 1 | 2014 | 53 | 0.400 |
Why?
| | Faculty | 1 | 2014 | 147 | 0.390 |
Why?
| | Students | 2 | 2017 | 622 | 0.380 |
Why?
| | Depressive Disorder, Major | 2 | 2006 | 364 | 0.380 |
Why?
| | Suicidal Ideation | 1 | 2017 | 529 | 0.370 |
Why?
| | Reproductive History | 2 | 2024 | 17 | 0.360 |
Why?
| | Postmenopause | 4 | 2014 | 366 | 0.360 |
Why?
| | Genotype | 14 | 2016 | 1916 | 0.350 |
Why?
| | Mental Health | 1 | 2017 | 726 | 0.340 |
Why?
| | Energy Metabolism | 4 | 2022 | 922 | 0.340 |
Why?
| | Phenotype | 4 | 2011 | 3196 | 0.340 |
Why?
| | Humans | 76 | 2024 | 137585 | 0.330 |
Why?
| | Mammography | 2 | 2009 | 154 | 0.330 |
Why?
| | Breast Feeding | 3 | 2019 | 440 | 0.320 |
Why?
| | Healthcare Disparities | 9 | 2016 | 654 | 0.320 |
Why?
| | Vocabulary, Controlled | 1 | 2010 | 47 | 0.320 |
Why?
| | Biomarkers, Tumor | 5 | 2024 | 1276 | 0.310 |
Why?
| | Polymorphism, Genetic | 4 | 2014 | 660 | 0.310 |
Why?
| | Alcoholism | 4 | 2017 | 807 | 0.300 |
Why?
| | California | 3 | 2024 | 431 | 0.290 |
Why?
| | Sex Characteristics | 4 | 2006 | 762 | 0.290 |
Why?
| | San Francisco | 4 | 2023 | 52 | 0.290 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2008 | 38 | 0.290 |
Why?
| | United States | 17 | 2024 | 14841 | 0.270 |
Why?
| | Aldehyde Oxidoreductases | 3 | 2004 | 27 | 0.270 |
Why?
| | Diet | 5 | 2015 | 1278 | 0.270 |
Why?
| | Estrogen Replacement Therapy | 1 | 2008 | 146 | 0.260 |
Why?
| | Medication Therapy Management | 2 | 2024 | 76 | 0.260 |
Why?
| | Hormones | 2 | 2012 | 143 | 0.250 |
Why?
| | Mexico | 5 | 2019 | 225 | 0.240 |
Why?
| | Odds Ratio | 7 | 2018 | 1070 | 0.240 |
Why?
| | Lipoproteins, HDL | 1 | 2005 | 77 | 0.230 |
Why?
| | Medicare Part D | 1 | 2024 | 25 | 0.220 |
Why?
| | Synoviocytes | 1 | 2024 | 16 | 0.220 |
Why?
| | Menstruation | 2 | 2021 | 43 | 0.220 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2024 | 54 | 0.220 |
Why?
| | Transforming Growth Factor beta | 3 | 2013 | 480 | 0.220 |
Why?
| | Life Style | 3 | 2015 | 490 | 0.210 |
Why?
| | Indians, North American | 6 | 2015 | 643 | 0.210 |
Why?
| | Mass Screening | 2 | 2009 | 1287 | 0.200 |
Why?
| | Universities | 2 | 2017 | 433 | 0.200 |
Why?
| | Pharmacies | 1 | 2023 | 38 | 0.200 |
Why?
| | Aged, 80 and over | 14 | 2024 | 7635 | 0.200 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2017 | 100 | 0.200 |
Why?
| | Algorithms | 2 | 2010 | 1704 | 0.190 |
Why?
| | Pharmaceutical Services | 1 | 2023 | 83 | 0.190 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2022 | 39 | 0.190 |
Why?
| | Blood Platelets | 1 | 2005 | 408 | 0.180 |
Why?
| | Southwestern United States | 5 | 2015 | 91 | 0.180 |
Why?
| | Health Status Disparities | 4 | 2017 | 289 | 0.180 |
Why?
| | Genetic Association Studies | 4 | 2022 | 377 | 0.180 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2021 | 46 | 0.180 |
Why?
| | Adiposity | 2 | 2016 | 518 | 0.170 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2014 | 234 | 0.170 |
Why?
| | Cholesterol, HDL | 1 | 2001 | 203 | 0.170 |
Why?
| | Logistic Models | 7 | 2020 | 2074 | 0.160 |
Why?
| | Immunohistochemistry | 1 | 2024 | 1738 | 0.160 |
Why?
| | Menarche | 1 | 2020 | 60 | 0.160 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 319 | 0.160 |
Why?
| | Age Factors | 6 | 2018 | 3295 | 0.160 |
Why?
| | Genetic Variation | 3 | 2014 | 991 | 0.160 |
Why?
| | Smoking | 3 | 2015 | 1627 | 0.150 |
Why?
| | Young Adult | 12 | 2021 | 13209 | 0.150 |
Why?
| | Bacteremia | 1 | 2021 | 214 | 0.150 |
Why?
| | Staphylococcal Infections | 2 | 2014 | 400 | 0.150 |
Why?
| | Premenopause | 4 | 2022 | 131 | 0.140 |
Why?
| | Anti-Bacterial Agents | 3 | 2024 | 1809 | 0.140 |
Why?
| | Drug Overdose | 1 | 2022 | 347 | 0.140 |
Why?
| | Myocardial Infarction | 2 | 2004 | 1046 | 0.140 |
Why?
| | Body Size | 2 | 2015 | 108 | 0.140 |
Why?
| | Pregnancy | 4 | 2024 | 6763 | 0.130 |
Why?
| | Incidence | 6 | 2016 | 2804 | 0.130 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2016 | 83 | 0.130 |
Why?
| | Body Mass Index | 7 | 2015 | 2389 | 0.120 |
Why?
| | Cigarette Smoking | 1 | 2017 | 101 | 0.120 |
Why?
| | Matrix Metalloproteinases | 2 | 2013 | 95 | 0.120 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2018 | 202 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2015 | 313 | 0.110 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2014 | 18 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 3 | 2024 | 361 | 0.110 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2014 | 77 | 0.110 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 1289 | 0.110 |
Why?
| | Aromatase | 1 | 2014 | 32 | 0.110 |
Why?
| | Waist Circumference | 1 | 2014 | 143 | 0.110 |
Why?
| | Selenoprotein P | 1 | 2013 | 3 | 0.110 |
Why?
| | Immunity | 1 | 2014 | 143 | 0.110 |
Why?
| | Oxidative Stress | 2 | 2013 | 1317 | 0.110 |
Why?
| | Postpartum Period | 2 | 2022 | 340 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2017 | 5472 | 0.100 |
Why?
| | Models, Educational | 1 | 2014 | 93 | 0.100 |
Why?
| | Male | 14 | 2024 | 67762 | 0.100 |
Why?
| | Social Justice | 1 | 2013 | 73 | 0.100 |
Why?
| | Endonucleases | 1 | 2013 | 32 | 0.100 |
Why?
| | Women's Health | 3 | 2016 | 372 | 0.100 |
Why?
| | Telomere Homeostasis | 1 | 2013 | 34 | 0.100 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2013 | 49 | 0.100 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2012 | 26 | 0.100 |
Why?
| | Genetics, Population | 1 | 2014 | 214 | 0.100 |
Why?
| | Tobacco Smoke Pollution | 1 | 2015 | 261 | 0.100 |
Why?
| | Infection Control | 1 | 2014 | 167 | 0.100 |
Why?
| | Schizosaccharomyces | 1 | 2014 | 92 | 0.100 |
Why?
| | Interleukins | 1 | 2014 | 250 | 0.100 |
Why?
| | Inflammation | 2 | 2014 | 2837 | 0.100 |
Why?
| | C-Reactive Protein | 1 | 2014 | 410 | 0.090 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2012 | 135 | 0.090 |
Why?
| | Prognosis | 5 | 2022 | 4030 | 0.090 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 301 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 382 | 0.090 |
Why?
| | Health Behavior | 1 | 2017 | 762 | 0.090 |
Why?
| | Genome | 1 | 2014 | 300 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 350 | 0.090 |
Why?
| | Aspirin | 1 | 2014 | 387 | 0.090 |
Why?
| | Polymerase Chain Reaction | 1 | 2014 | 1062 | 0.090 |
Why?
| | Risk | 4 | 2015 | 912 | 0.090 |
Why?
| | Perception | 1 | 2014 | 359 | 0.090 |
Why?
| | Dietary Fats | 2 | 2015 | 304 | 0.090 |
Why?
| | Obesity | 3 | 2016 | 2992 | 0.090 |
Why?
| | Registries | 3 | 2018 | 2035 | 0.090 |
Why?
| | Telomerase | 1 | 2013 | 250 | 0.080 |
Why?
| | Research | 1 | 2014 | 451 | 0.080 |
Why?
| | Breast | 3 | 2017 | 151 | 0.080 |
Why?
| | Telomere | 1 | 2013 | 280 | 0.080 |
Why?
| | Anxiety | 1 | 2017 | 1035 | 0.080 |
Why?
| | Cross Infection | 1 | 2012 | 256 | 0.080 |
Why?
| | Risk Assessment | 4 | 2022 | 3457 | 0.080 |
Why?
| | RNA | 1 | 2016 | 921 | 0.080 |
Why?
| | Mammary Glands, Human | 1 | 2010 | 64 | 0.080 |
Why?
| | Weight Gain | 1 | 2013 | 519 | 0.080 |
Why?
| | Mammary Glands, Animal | 1 | 2010 | 129 | 0.080 |
Why?
| | Gene-Environment Interaction | 3 | 2015 | 192 | 0.080 |
Why?
| | Population Surveillance | 3 | 2018 | 482 | 0.080 |
Why?
| | Macrophage Activation | 1 | 2010 | 201 | 0.070 |
Why?
| | Natural Language Processing | 1 | 2010 | 95 | 0.070 |
Why?
| | Transcription Factors | 2 | 2013 | 1719 | 0.070 |
Why?
| | Depression | 1 | 2017 | 1397 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5131 | 0.070 |
Why?
| | Proteomics | 2 | 2006 | 1111 | 0.070 |
Why?
| | Liver | 1 | 2016 | 1943 | 0.070 |
Why?
| | Family Health | 1 | 2008 | 196 | 0.070 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 530 | 0.070 |
Why?
| | Collagen | 1 | 2010 | 452 | 0.070 |
Why?
| | Exercise | 2 | 2017 | 2057 | 0.070 |
Why?
| | Research Design | 1 | 2014 | 1139 | 0.070 |
Why?
| | Homozygote | 2 | 2013 | 203 | 0.070 |
Why?
| | Ovarian Neoplasms | 1 | 2013 | 565 | 0.070 |
Why?
| | Eye Proteins | 1 | 2007 | 92 | 0.070 |
Why?
| | Neoplasm Staging | 3 | 2016 | 1389 | 0.070 |
Why?
| | O(6)-Methylguanine-DNA Methyltransferase | 1 | 2006 | 6 | 0.060 |
Why?
| | Colorado | 2 | 2014 | 4565 | 0.060 |
Why?
| | Colorectal Neoplasms | 2 | 2006 | 806 | 0.060 |
Why?
| | Cornea | 1 | 2007 | 138 | 0.060 |
Why?
| | Biomarkers | 3 | 2010 | 4149 | 0.060 |
Why?
| | Genetic Linkage | 1 | 2006 | 297 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2008 | 1946 | 0.060 |
Why?
| | Lens, Crystalline | 1 | 2007 | 125 | 0.060 |
Why?
| | DNA, Complementary | 1 | 2006 | 272 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1502 | 0.060 |
Why?
| | International Agencies | 1 | 2005 | 35 | 0.060 |
Why?
| | Patient Compliance | 1 | 2009 | 581 | 0.060 |
Why?
| | World Health Organization | 1 | 2005 | 123 | 0.060 |
Why?
| | Giant Cell Tumor of Tendon Sheath | 1 | 2024 | 4 | 0.060 |
Why?
| | Adolescent | 6 | 2021 | 21513 | 0.060 |
Why?
| | Antioxidants | 1 | 2008 | 584 | 0.060 |
Why?
| | Cataract | 1 | 2007 | 213 | 0.060 |
Why?
| | Sex Distribution | 1 | 2005 | 375 | 0.050 |
Why?
| | Cause of Death | 2 | 2016 | 434 | 0.050 |
Why?
| | Gene Frequency | 1 | 2005 | 521 | 0.050 |
Why?
| | Retinal Dehydrogenase | 2 | 2017 | 29 | 0.050 |
Why?
| | Bacterial Typing Techniques | 2 | 2014 | 44 | 0.050 |
Why?
| | Databases, Bibliographic | 1 | 2003 | 32 | 0.050 |
Why?
| | Pneumonia, Bacterial | 1 | 2024 | 116 | 0.050 |
Why?
| | Antidepressive Agents | 1 | 2005 | 236 | 0.050 |
Why?
| | Prevalence | 1 | 2010 | 2734 | 0.050 |
Why?
| | Soft Tissue Neoplasms | 1 | 2024 | 115 | 0.050 |
Why?
| | Ohio | 2 | 2014 | 152 | 0.050 |
Why?
| | Genome-Wide Association Study | 3 | 2015 | 1431 | 0.050 |
Why?
| | Linear Models | 1 | 2005 | 849 | 0.050 |
Why?
| | Signal Transduction | 5 | 2016 | 5079 | 0.050 |
Why?
| | Spatio-Temporal Analysis | 1 | 2022 | 34 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2139 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1325 | 0.050 |
Why?
| | Antimicrobial Stewardship | 1 | 2024 | 118 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2900 | 0.050 |
Why?
| | Macrophages | 1 | 2010 | 1547 | 0.050 |
Why?
| | Communicable Disease Control | 1 | 2022 | 82 | 0.050 |
Why?
| | Homeostasis | 2 | 2016 | 621 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2531 | 0.050 |
Why?
| | Mice, Transgenic | 1 | 2006 | 2167 | 0.040 |
Why?
| | Hemostasis | 1 | 2001 | 82 | 0.040 |
Why?
| | Blood Culture | 1 | 2021 | 23 | 0.040 |
Why?
| | Patient Safety | 1 | 2024 | 314 | 0.040 |
Why?
| | Gram-Negative Bacteria | 1 | 2021 | 73 | 0.040 |
Why?
| | Age of Onset | 2 | 2016 | 518 | 0.040 |
Why?
| | Societies, Medical | 1 | 2005 | 820 | 0.040 |
Why?
| | Survivors | 2 | 2016 | 493 | 0.040 |
Why?
| | Quality Indicators, Health Care | 1 | 2023 | 307 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 405 | 0.040 |
Why?
| | Isoenzymes | 1 | 2001 | 304 | 0.040 |
Why?
| | Neoplasm Invasiveness | 2 | 2016 | 510 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2010 | 5757 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2022 | 2031 | 0.040 |
Why?
| | Survival Rate | 2 | 2014 | 1972 | 0.040 |
Why?
| | Ethanol | 1 | 2004 | 608 | 0.040 |
Why?
| | Biomedical Research | 1 | 2005 | 692 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2022 | 1266 | 0.040 |
Why?
| | Pneumonia | 1 | 2024 | 639 | 0.040 |
Why?
| | Computational Biology | 1 | 2003 | 644 | 0.040 |
Why?
| | Regression Analysis | 1 | 2001 | 1024 | 0.040 |
Why?
| | Genomics | 1 | 2003 | 795 | 0.040 |
Why?
| | Animals | 5 | 2016 | 36940 | 0.030 |
Why?
| | Cohort Studies | 2 | 2022 | 5742 | 0.030 |
Why?
| | Utah | 1 | 2017 | 69 | 0.030 |
Why?
| | Lipids | 1 | 2001 | 672 | 0.030 |
Why?
| | Lod Score | 1 | 2016 | 67 | 0.030 |
Why?
| | Rats, Inbred SHR | 1 | 2016 | 45 | 0.030 |
Why?
| | Gene Ontology | 1 | 2016 | 53 | 0.030 |
Why?
| | Poultry | 1 | 2016 | 10 | 0.030 |
Why?
| | Neuropeptide Y | 1 | 2016 | 14 | 0.030 |
Why?
| | Cholecystokinin | 1 | 2016 | 12 | 0.030 |
Why?
| | Receptors, Ghrelin | 1 | 2016 | 8 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 314 | 0.030 |
Why?
| | Red Meat | 1 | 2016 | 18 | 0.030 |
Why?
| | Receptors, Leptin | 1 | 2016 | 23 | 0.030 |
Why?
| | Mice | 3 | 2010 | 17787 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 268 | 0.030 |
Why?
| | SEER Program | 1 | 2016 | 227 | 0.030 |
Why?
| | Survival | 1 | 2015 | 38 | 0.030 |
Why?
| | Fishes | 1 | 2016 | 105 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase Phosphatases | 1 | 2015 | 2 | 0.030 |
Why?
| | MAP Kinase Kinase Kinase 2 | 1 | 2015 | 12 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 14 | 1 | 2015 | 7 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2015 | 16 | 0.030 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2015 | 11 | 0.030 |
Why?
| | Meat | 1 | 2016 | 94 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 554 | 0.030 |
Why?
| | Immune System | 1 | 2016 | 177 | 0.030 |
Why?
| | Interviews as Topic | 2 | 2008 | 786 | 0.030 |
Why?
| | Prospective Studies | 2 | 2013 | 7604 | 0.030 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2014 | 12 | 0.030 |
Why?
| | Dietary Fiber | 1 | 2015 | 54 | 0.030 |
Why?
| | Population Groups | 1 | 2015 | 62 | 0.030 |
Why?
| | Janus Kinase 1 | 1 | 2014 | 24 | 0.030 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2014 | 21 | 0.030 |
Why?
| | Janus Kinase 2 | 1 | 2014 | 32 | 0.030 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2015 | 73 | 0.030 |
Why?
| | Hospitalization | 1 | 2024 | 2199 | 0.030 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2014 | 24 | 0.030 |
Why?
| | STAT1 Transcription Factor | 1 | 2014 | 72 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1000 | 0.030 |
Why?
| | Molecular Epidemiology | 1 | 2014 | 68 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2015 | 185 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2016 | 380 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2014 | 113 | 0.030 |
Why?
| | Hospitals, Community | 1 | 2014 | 52 | 0.030 |
Why?
| | Genes, sis | 1 | 2013 | 1 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1639 | 0.030 |
Why?
| | Fibroblast Growth Factor 1 | 1 | 2013 | 13 | 0.030 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2013 | 27 | 0.030 |
Why?
| | Genes, erbB-2 | 1 | 2013 | 28 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 452 | 0.030 |
Why?
| | Folic Acid | 1 | 2015 | 186 | 0.030 |
Why?
| | Matrix Metalloproteinase 1 | 1 | 2013 | 22 | 0.030 |
Why?
| | Matrix Metalloproteinase 3 | 1 | 2013 | 28 | 0.030 |
Why?
| | DNA, Neoplasm | 1 | 2013 | 164 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 86 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2013 | 56 | 0.030 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2013 | 87 | 0.030 |
Why?
| | Nerve Growth Factors | 1 | 2013 | 79 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 71 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2013 | 173 | 0.030 |
Why?
| | Platinum | 1 | 2013 | 50 | 0.030 |
Why?
| | Peroxidase | 1 | 2013 | 175 | 0.020 |
Why?
| | Drug Interactions | 1 | 2014 | 410 | 0.020 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 177 | 0.020 |
Why?
| | New Mexico | 1 | 2013 | 92 | 0.020 |
Why?
| | Arizona | 1 | 2013 | 81 | 0.020 |
Why?
| | Molecular Typing | 1 | 2012 | 22 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 132 | 0.020 |
Why?
| | Genomic Instability | 1 | 2013 | 53 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2014 | 347 | 0.020 |
Why?
| | Heterozygote | 1 | 2013 | 293 | 0.020 |
Why?
| | Energy Intake | 1 | 2015 | 485 | 0.020 |
Why?
| | Catheterization | 1 | 2012 | 179 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 278 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2013 | 686 | 0.020 |
Why?
| | Smoking Cessation | 1 | 2015 | 442 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2014 | 443 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2014 | 512 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 494 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2013 | 545 | 0.020 |
Why?
| | Alleles | 1 | 2013 | 891 | 0.020 |
Why?
| | Cell Movement | 2 | 2006 | 967 | 0.020 |
Why?
| | Weaning | 1 | 2010 | 47 | 0.020 |
Why?
| | Transcriptome | 1 | 2016 | 971 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2015 | 5778 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2844 | 0.020 |
Why?
| | Renal Dialysis | 1 | 2012 | 435 | 0.020 |
Why?
| | Species Specificity | 1 | 2010 | 585 | 0.020 |
Why?
| | Tocopherols | 1 | 2008 | 26 | 0.020 |
Why?
| | Carotenoids | 1 | 2008 | 43 | 0.020 |
Why?
| | Vitamin A | 1 | 2008 | 58 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 985 | 0.020 |
Why?
| | Diet Records | 1 | 2008 | 83 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2012 | 645 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2013 | 801 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2008 | 329 | 0.020 |
Why?
| | Factor Analysis, Statistical | 1 | 2008 | 283 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 2008 | 177 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6828 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 156 | 0.020 |
Why?
| | Attitude to Health | 1 | 2009 | 439 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2010 | 528 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 2757 | 0.020 |
Why?
| | Glutathione | 1 | 2007 | 356 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 396 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2486 | 0.010 |
Why?
| | Mood Disorders | 1 | 2005 | 133 | 0.010 |
Why?
| | Receptors, Estradiol | 1 | 2003 | 3 | 0.010 |
Why?
| | Software Validation | 1 | 2003 | 10 | 0.010 |
Why?
| | MEDLINE | 1 | 2003 | 21 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2007 | 1060 | 0.010 |
Why?
| | Forecasting | 1 | 2005 | 389 | 0.010 |
Why?
| | Motor Activity | 1 | 2008 | 718 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 2003 | 88 | 0.010 |
Why?
| | Disease | 1 | 2003 | 98 | 0.010 |
Why?
| | Databases, Genetic | 1 | 2003 | 237 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2004 | 955 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2006 | 956 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2003 | 499 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2003 | 363 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2006 | 1993 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 767 | 0.010 |
Why?
| | Rats | 1 | 2010 | 5647 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2009 | 1329 | 0.010 |
Why?
| | Bipolar Disorder | 1 | 2003 | 263 | 0.010 |
Why?
| | Comorbidity | 1 | 2005 | 1622 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2007 | 3015 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2006 | 1774 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1502 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2006 | 3412 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2004 | 1096 | 0.010 |
Why?
| | Aging | 1 | 2007 | 1864 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 1 | 2003 | 1167 | 0.010 |
Why?
| | Hypertension | 1 | 2003 | 1295 | 0.010 |
Why?
|
|
Hines's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|